



Dr. Alvaro Pereira, Clinical Research Scientist Advisor, will participate in the Breakfast Briefing (20 May 2010) with Dr. Lars Arendt-Nielsen during the **Exploratory Clinical Development World congress** taking place in London on 18-21 May 2010.

Abstract title:

“Are pain models predictive or efficacy? Myth or reality?”

The current and major challenge in developing new medication for chronic pain is the characterization and validation of translational links from animals’ models to patients and vice versa, pain diseases to pain mechanisms and lastly pain diseases and symptoms.

Designing an optimal early clinical development plan for a chronic pain compound is complex and challenging. It should test for various pain mechanisms as well trying to translate these mechanisms in very well characterized patient populations. Each characterisation represents an equivalent of proof of mechanism per se, if successful.

We will attempt to review translational animal and human pain models approaches and will present examples of strategies (including their limitations) for developing new pain molecules. Inclusion of healthy volunteers versus patients will be evaluated and commented, as well as examples of various pain models (from the simplest to the most complex ones).

This session will address:

Introduction: Pain and attrition rate

Pain mechanism: Symptoms to clinic

Pain models: preclinical and healthy/patients

Strategy for developing pain molecules: relevant data influencing the early clinical strategy

Examples of 2 hypothetical classes of molecules

Summary/Conclusions